Patents Assigned to Kota Biotherapeutics, LLC
  • Publication number: 20210095010
    Abstract: Compositions and methods are disclosed herein for producing one or more immunoglobulins in an isolated cytotoxic B lymphocyte cell line. An isolated cell line includes an isolated B lymphocyte cell line capable of expressing at least one exogenously incorporated membrane immunoglobulin capable of binding to a first antigen and at least one endogenous secreted immunoglobulin capable of binding to a second antigen, and further capable of expressing at least one exogenously incorporated recombinant B cell receptor that signals for expression of cytotoxic effector molecules.
    Type: Application
    Filed: August 17, 2020
    Publication date: April 1, 2021
    Applicant: KOTA BIOTHERAPEUTICS, LLC
    Inventors: Roderick A. Hyde, Wayne R. Kindsvogel, Gary L. McKnight
  • Patent number: 10745468
    Abstract: Compositions and methods are disclosed herein for producing one or more immunoglobulins in an isolated cytotoxic B lymphocyte cell line. An isolated cell line includes an isolated B lymphocyte cell line capable of expressing at least one exogenously incorporated membrane immunoglobulin capable of binding to a first antigen and at least one endogenous secreted immunoglobulin capable of binding to a second antigen, and further capable of expressing at least one exogenously incorporated recombinant B cell receptor that signals for expression of cytotoxic effector molecules.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: August 18, 2020
    Assignee: Kota Biotherapeutics, LLC
    Inventors: Roderick A. Hyde, Wayne R. Kindsvogel, Gary L. McKnight
  • Patent number: 10597442
    Abstract: Compositions and methods are disclosed herein for producing one or more immunoglobulins in an isolated cytotoxic B lymphocyte cell line. An isolated cell line includes an isolated B lymphocyte cell line capable of expressing at least one exogenously incorporated membrane immunoglobulin capable of binding to a first antigen and at least one endogenous secreted immunoglobulin capable of binding to a second antigen, and further capable of expressing at least one exogenously incorporated recombinant B cell receptor that signals for expression of cytotoxic effector molecules.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: March 24, 2020
    Assignee: Kota Biotherapeutics, LLC
    Inventors: Roderick A. Hyde, Wayne R. Kindsvogel, Gary L. McKnight